SAN DIEGO, Jan. 25, 2017 /PRNewswire/ -- Shareholder
Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Pearson plc, BT Group plc, Dr. Reddy's
Laboratories Ltd., and OneMain Holdings, Inc., as detailed below:
Pearson plc
Shareholder rights law firm Johnson & Weaver, LLP continues its investigation of potential violations of the federal
securities laws by Pearson plc (NYSE: PSO) and certain of its officers.
On January 18, 2017, Pearson said that its initial projections about its U.S. educational
business had been too high and students are balking at paying top-dollar for textbooks when more affordable alternatives to
outright purchases are available. The result has been an excess of unsold books. Pearson also signaled that a dividend cut would
be coming in 2017. Pearson shares were down 29% on January 18, 2017.
After Pearson's announcement, Moody's Investors Service changed the outlook on the Company ratings to negative from
stable.
If you have information that could assist in this investigation, or if you are a Pearson shareholder and are
interested in learning more about the investigation or your legal rights and remedies, please contact Jim
Baker (jimb@johnsonandweaver.com) by
email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
BT Group plc
Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers
of BT Group plc (NYSE: BT) from March 3, 2015, through November 7, 2016, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for BT
investors under the federal securities laws.
According to the lawsuit, throughout the Class Period Defendants made false and misleading statements and failed to disclose
that: (1) BT Group misstated its earnings due to improper accounting practices and improper sales, purchase, factoring and
leasing transactions in its Italian operations; (2) BT Group lacked effective internal controls; and (3) as a result, Defendants'
statements about BT Group's business, operations and prospects were materially false and misleading and lacked a reasonable basis
at all relevant times.
If you wish to serve as a lead plaintiff, you must move the Court no later than March 27,
2017. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please
contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
Dr. Reddy's Laboratories Ltd.
Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and certain of its officers. Dr. Reddy's operates as an integrated
pharmaceutical company worldwide.
On November 6, 2015, Dr. Reddy's reported that the Company received a "warning letter" from U.S.
regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases.
Dr. Reddy's said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the
problems. The manufacturing plants account for more than 10 percent to 12 percent of Dr. Reddy's sales.
If you have information that could assist in this investigation, or if you are a Dr. Reddy's
shareholder and purchased before November 9, 2015, and are interested in learning
more about the investigation or your legal rights and remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) by email or
by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
OneMain Holdings, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers
of OneMain Holdings, Inc. securities (NYSE: OMF) from March 3, 2015, through November 7, 2016, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for OneMain
investors.
According to the lawsuit, defendants throughout the Class Period caused OneMain to issue materially misleading representations
and omit material information regarding the projected net income to be achieved by OneMain following, and in large part due to,
the combination of OneMain Financial with Springleaf and the purported synergies achieved by the combined company.
If you wish to serve as a lead plaintiff, you must move the Court no later than March 20,
2017. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please
contact lead analyst Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm
represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--weaver-llp-announces-investigations-of-pearson-plc-bt-group-plc-dr-reddys-laboratories-ltd-and-onemain-holdings-inc-300396847.html
SOURCE Johnson & Weaver, LLP